Schonfeld Strategic Advisors LLC Buys New Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Schonfeld Strategic Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 72,980 shares of the biopharmaceutical company's stock, valued at approximately $1,523,000. Schonfeld Strategic Advisors LLC owned approximately 0.06% of Catalyst Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. AQR Capital Management LLC grew its position in shares of Catalyst Pharmaceuticals by 3.8% in the 4th quarter. AQR Capital Management LLC now owns 477,011 shares of the biopharmaceutical company's stock valued at $9,955,000 after buying an additional 17,659 shares during the last quarter. Lido Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 12.0% during the fourth quarter. Lido Advisors LLC now owns 24,658 shares of the biopharmaceutical company's stock worth $515,000 after purchasing an additional 2,650 shares in the last quarter. Northern Trust Corp increased its position in shares of Catalyst Pharmaceuticals by 8.7% during the fourth quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock worth $31,379,000 after purchasing an additional 119,766 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $1,243,000. Finally, Quarry LP purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $104,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX traded up $0.19 on Monday, hitting $23.56. 271,649 shares of the company's stock were exchanged, compared to its average volume of 1,106,807. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 3.31 and a beta of 0.70. The firm's 50-day moving average price is $22.99 and its two-hundred day moving average price is $22.40.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Finally, Stephens reissued an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $32.29.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their position. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.